Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Phase 1/2 Study to Explore the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of TRX-221 in the Treatment of Patients With EGFR Mutant NSCLC Who Progressed Following Prior Therapy With EGFR TKI

NCT06186076 is registered in ClinicalTrials.gov with Therapex Co., Ltd as lead sponsor.

NCT NCT06186076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06186076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Phase 1/2 Study to Explore the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of TRX-221 in the Treatment of Patients With EGFR Mutant NSCLC Who Progressed Following Prior Therapy With EGFR TKI
Lead sponsor
Therapex Co., Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
June 14, 2024
Completion date
December 3, 2025
Enrollment
19 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, egfr mutant advanced non-small cell lung cancer